Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Painkyl for Breakthrough Cancer Pain in Taiwanese Patients
NCT03669263Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Nov 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Painkyl in breakthrough cancer pain (BTcP), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Optimal dose of Painkyl at 2 weeks. Started Nov 2014; status: completed.
02
Drugs
Painkyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT03669263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669263.